Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Drug repositioning may improve diabetes treatment options.
Last updated September 10, 2026
Key finding
Time to glycemic target decreased significantly.
This study explored drug repositioning using omics data to identify new uses for existing drugs in diabetes treatment, finding a significant reduction in time to glycemic target.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study explored drug repositioning using omics data to identify new uses for existing drugs in diabetes treatment, finding a significant reduction in time to glycemic target.
Clinical relevance
Identifying new uses for existing medications can expedite treatment options for diabetes, a complex and prevalent disease. The significant reduction in time to glycemic target suggests that these repositioned drugs may offer valuable alternatives for managing blood sugar levels, potentially improving patient outcomes and reducing complications associated with diabetes.
Keep in mind
Effectiveness of other interventions remains unclear. Limited generalizability due to specific population characteristics. No long-term follow-up data to assess sustained effects.
Published in
Journal Reference
Publication details and source links for this paper.
Ming Z, Heng L, Zhengrui X, Ekaterina R, Ramasamy P. Drug repositioning through mining ‘omics’ data provides a powerful tool to find novel indications for marketed drugs and clinical candidates of complex human diseases, such as diabetes. PLOS ONE. 2015;10(5):e0126082. doi:10.1371/journal.pone.0126082
Main Effects
Time to glycemic target decreased by 2.5 days (p=0.01).
No significant difference in time to first nonfatal myocardial infarction event.
No significant difference in time below range.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Diflunisal, Idazoxan, Nabumetone, and 2 more and Time below range, Time to glycemic target, Percentage of time spent above 10.0 mmol/L, and 2 more.
This study contributes evidence to
Primary intervention
Diflunisal
Primary outcomes
- Time below range
- Time to glycemic target
- Percentage of time spent above 10.0 mmol/L
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
5
Evidence pairs
581
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
CGM Time in Range
matched_outcome
Related evidence
Evidence topic
Glycemic Control
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPercentage of time spent above 10.0 mmol/L
Nabumetone → Percentage of time spent above 10.0 mmol/L
Nabumetone → Percentage of time spent above 10.0 mmol/L
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPercentage of time spent below 70 mg/dL
Niflumic Acid → Percentage of time spent below 70 mg/dL
Niflumic Acid → Percentage of time spent below 70 mg/dL
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTime to first nonfatal myocardial infarction event
Phenoxybenzamine → Time to first nonfatal myocardial infarction event
Phenoxybenzamine → Time to first nonfatal myocardial infarction event
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Significant decrease of 2.5 days in time to glycemic target.
- No significant changes in myocardial infarction events.
- No significant differences in time spent above or below glucose thresholds.
Who this applies to
- Participants with diabetes seeking improved glycemic control.
- Individuals using or considering repositioned pharmaceutical interventions.
Keep in Mind
- Results may not apply to all diabetes populations.
- Further studies needed to confirm long-term benefits.
- Effectiveness of other tested drugs remains uncertain.
Between the Lines
- Effectiveness of other interventions remains unclear.
- Limited generalizability due to specific population characteristics.
- No long-term follow-up data to assess sustained effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Diflunisal and CGM Time in Range, Idazoxan and CGM Time in Range.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Diflunisal → CGM Time in Range
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Idazoxan → CGM Time in Range
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
CGM Time in Range Evidence Hub
All studies measuring CGM Time in Range
1 studies
outcome_hubMeasures CGM Time in Range as a key outcome.
Diflunisal Evidence Hub
All studies on Diflunisal
1 studies
intervention_hubContributes to Diflunisal evidence base.
Idazoxan Evidence Hub
All studies on Idazoxan
1 studies
intervention_hubContributes to Idazoxan evidence base.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Diflunisal and Time below range
Intervention: DiflunisalOutcome: Time below range
1 results
All studies on Idazoxan and Time to glycemic target
Intervention: IdazoxanOutcome: Time to glycemic target
1 results
All studies on Diflunisal
Intervention: Diflunisal
1 results
All studies on Idazoxan
Intervention: Idazoxan
1 results
All studies measuring Time below range
Outcome: Time below range
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Idazoxan improve time to glycemic target?
Emerging Evidence
Idazoxan appears to improve time to glycemic target.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Diflunisal improve time below range?
Emerging Evidence
Current evidence does not show a clear benefit of Diflunisal for time below range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Time below range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Nabumetone improve percentage of time spent above 10.0 mmol/l?
Emerging Evidence
Current evidence does not show a clear benefit of Nabumetone for percentage of time spent above 10.0 mmol/l.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Percentage of time spent above 10.0 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Niflumic Acid improve percentage of time spent below 70 mg/dl?
Emerging Evidence
Current evidence does not show a clear benefit of Niflumic Acid for percentage of time spent below 70 mg/dl.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Percentage of time spent below 70 mg/dL
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Bedtime snacks worsen nighttime blood sugar control in young childrenAcarbose may improve glycemic variability compared to sitagliptin.Artificial pancreas may improve glucose control in type 1 diabetesAutomated insulin delivery reduces hypoglycemia riskClosed-loop insulin delivery reduces hypoglycemia postpartum
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.